MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
11.73
-0.23
-1.88%
Opening 09:51 02/11 EST
OPEN
11.98
PREV CLOSE
11.95
HIGH
12.20
LOW
11.60
VOLUME
260.41K
TURNOVER
--
52 WEEK HIGH
12.48
52 WEEK LOW
1.010
MARKET CAP
3.59B
P/E (TTM)
-26.0209
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Erasca (ERAS) and Pharvaris (PHVS)
TipRanks · 2d ago
Weekly Report: what happened at ERAS last week (0202-0206)?
Weekly Report · 2d ago
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline
Simply Wall St · 5d ago
Erasca Inc. to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference
Reuters · 6d ago
Assessing Erasca (ERAS) Valuation After A Powerful Share Price Run And High Price To Book Premium
Simply Wall St · 02/03 14:21
Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?
Barchart · 02/02 11:45
Weekly Report: what happened at ERAS last week (0126-0130)?
Weekly Report · 02/02 10:19
Erasca CFO and CBO David M. Chacko Reports Acquisition of Common Shares
Reuters · 01/30 14:04
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.